4.7 Article

Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2

Journal

NEUROLOGY
Volume 76, Issue 24, Pages 2066-2072

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31821f445b

Keywords

-

Funding

  1. Health Seventh Framework Programme [FP7/2007-2013, 259867]
  2. Belgian Federal Science Policy Office [P6/43]
  3. University of Leuven [GOA 11/014]
  4. E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders
  5. Biogen Idec Chair Translational Research in Multiple Sclerosis
  6. Bayer Schering Pharma Chair on Fundamental Research
  7. Brain Foundation of the Netherlands
  8. Prinses Beatrix Fonds
  9. Netherlands ALS Foundation
  10. VSB Fonds
  11. Adessium Foundation
  12. FWO-Vlaanderen
  13. Baxter International Inc.
  14. Shire plc
  15. Boehringer Ingelheim
  16. SERVIER
  17. Schering-Plough Corp.
  18. SYGNIS Pharma AG
  19. CoAxia, Inc.
  20. Medtronic, Inc.
  21. Novo Nordisk
  22. Bristol-Myers Squibb
  23. Pfizer Inc
  24. AstraZeneca
  25. ThromboGenics NV
  26. Eli Lilly and Company
  27. sanofi-aventis
  28. Daiichi Sankyo
  29. Asubio Pharmaceuticals, Inc.
  30. FWO Flanders
  31. Vlaams Instituut voor Biotechnologie
  32. Novartis
  33. Merck Serono
  34. Bayer Schering Pharma
  35. Biogen Idec
  36. Neuronova
  37. TEVA
  38. Trophos
  39. T. Latran Foundation, Paris (France)
  40. Packard Center for ALS research (USA)

Ask authors/readers for more resources

Objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons that results in progressive muscle weakness and limits survival to 2-5 years after disease onset. Intermediate CAG repeat expansions in ataxin 2 (ATXN2), the causative gene of spinocerebellar ataxia type 2 (SCA2), have been implicated in sporadic ALS. We studied ATXN2 in a large cohort of patients with sporadic and familial ALS. Methods: We determined ATXN2 CAG repeat size in 1,948 sporadic and familial ALS cases and 2,002 controls from Belgium and the Netherlands. Results: In controls, the maximal ATXN2 repeat size was 31. In sporadic ALS, a significant amount of longer repeat sizes (>= 32, range 32-39) were encountered (in 0.5% or 10/1,845 ALS cases, vs 0% in controls, p = 0.0006). Receiver operating characteristic analysis showed that a cutoff of >= 29 appeared optimal to discriminate ALS from control (p = 0.036, odds ratio [OR] 1.92, 95% confidence interval [CI] 1.04-3.64). A meta-analysis with the previously published results from the United States showed that the association between a repeat length of >= 29 and ALS became stronger (p < 0.0001, OR 2.93, 95% CI 1.73-4.98). In unexplained familial ALS, we found an intermediate repeat expansion of 31 and a homozygous repeat expansion of 33 each in 1.1% of families. The phenotype of patients with ALS with expanded repeat sizes ranged from rapidly progressive typical ALS to slowly progressive ALS with reduced sensory nerve action potentials. Conclusion: Our data reveal a novel genetic overlap between ALS and SCA2. Neurology (R) 2011; 76: 2066-2072

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available